Helius Medical Technologies, Inc. (HSDT)
Automate Your Wheel Strategy on HSDT
With Tiblio's Option Bot, you can configure your own wheel strategy including HSDT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol HSDT
- Rev/Share 0.0574
- Book/Share 0.1694
- PB 32.7635
- Debt/Equity 0.0
- CurrentRatio 1.69
- ROIC -9.7893
- MktCap 41937282.0
- FreeCF/Share -1.532
- PFCF -3.6228
- PE -3.2101
- Debt/Assets 0.0
- DivYield 0
- ROE -4.1882
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Helius Announces Positive Outcome of the Portable Neuromodulation Stimulator PoNS® Stroke Registrational Program and Upcoming Submission to FDA Under Breakthrough Designation
Published: July 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEWTOWN, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced positive outcome from the PoNS (Portable Neuromodulation Stimulator) Stroke Registrational Program (SRP) supporting a planned FDA submission seeking an indication for gait and balance deficit in patients with chronic symptoms of stroke under the current Breakthrough Device Designation.
Read More
Helius Medical Technologies Announces Pricing of $9.1 Million Public Offering
Published: June 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEWTOWN, Pa., June 04, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced the pricing of its public offering of an aggregate of 2,768,600 shares of its Class A common stock (or common stock equivalents), and warrants to purchase up to 2,768,600 shares of common stock, at a combined public offering price of $3.27 per share and accompanying warrants.
Read More
Helius Medical Technologies, Inc. Announces Reimbursement by Major Healthcare Provider for its Portable Neuromodulation Stimulator (PoNS®) Device
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
United Healthcare approves claim for PoNS Device at out-of-network adjusted list price, becoming the second payer to join Anthem in providing PoNS reimbursement United Healthcare approves claim for PoNS Device at out-of-network adjusted list price, becoming the second payer to join Anthem in providing PoNS reimbursement
Read More
Helius Medical Technologies Announces Reverse Stock Split
Published: April 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEWTOWN, Pa., April 30, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, announced today a 1-for-15 reverse split of its Class A common stock, par value $0.001 (“common stock”), effective at 5:00 pm Eastern time on May 1, 2025.
Read More
About Helius Medical Technologies, Inc. (HSDT)
- IPO Date 2014-06-27
- Website https://heliusmedical.com
- Industry Medical - Devices
- CEO Dane Carl Andreeff
- Employees 21